Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.
Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, de la Revilla J, Hansen BE, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Papatheodoridis G, et al. Among authors: sypsa v. J Hepatol. 2016 Apr;64(4):800-6. doi: 10.1016/j.jhep.2015.11.035. Epub 2015 Dec 8. J Hepatol. 2016. PMID: 26678008
Significance of IgM anti-HCV core level in chronic hepatitis C.
Papatheodoridis GV, Delladetsima JK, Katsoulidou A, Sypsa V, Albrecht M, Michel G, Hatzakis A, Tassopoulos NC. Papatheodoridis GV, et al. Among authors: sypsa v. J Hepatol. 1997 Jul;27(1):36-41. doi: 10.1016/s0168-8278(97)80277-2. J Hepatol. 1997. PMID: 9252071
A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1.
Tassopoulos NC, Tsantoulas D, Raptopoulou M, Vassiliadis T, Kanatakis S, Paraskevas E, Vafiadis I, Avgerinos A, Tzathas C, Manolakopoulos S, Ketikoglou I, Aggelis P, Goritsas K, Giannoulis G, Hatzis G G, Thomopoulos K, Akriviadis E, Sypsa V, Hatzakis A. Tassopoulos NC, et al. Among authors: sypsa v. J Viral Hepat. 2003 May;10(3):189-96. doi: 10.1046/j.1365-2893.2003.00406.x. J Viral Hepat. 2003. PMID: 12753337 Clinical Trial.
Quantitative detection of the M204V hepatitis B virus minor variants by amplification refractory mutation system real-time PCR combined with molecular beacon technology.
Ntziora F, Paraskevis D, Haida C, Magiorkinis E, Manesis E, Papatheodoridis G, Manolakopoulos S, Beloukas A, Chryssoy S, Magiorkinis G, Sypsa V, Hatzakis A. Ntziora F, et al. Among authors: sypsa v. J Clin Microbiol. 2009 Aug;47(8):2544-50. doi: 10.1128/JCM.00045-09. Epub 2009 Jun 24. J Clin Microbiol. 2009. PMID: 19553583 Free PMC article.
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.
Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, Keskın O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Papatheodoridis GV, et al. Among authors: sypsa v. J Hepatol. 2015 Feb;62(2):363-70. doi: 10.1016/j.jhep.2014.08.045. Epub 2014 Sep 6. J Hepatol. 2015. PMID: 25195548
167 results